Gen Ilac Ve Saglik Urunleri Sanayi Ve Ticaret Anonim Sirketi Past Earnings Performance
Past criteria checks 2/6
Gen Ilac Ve Saglik Urunleri Sanayi Ve Ticaret Anonim Sirketi has been growing earnings at an average annual rate of 20%, while the Pharmaceuticals industry saw earnings growing at 9.4% annually. Revenues have been growing at an average rate of 40.8% per year. Gen Ilac Ve Saglik Urunleri Sanayi Ve Ticaret Anonim Sirketi's return on equity is 8.7%, and it has net margins of 5%.
Key information
20.0%
Earnings growth rate
-13.6%
EPS growth rate
| Pharmaceuticals Industry Growth | 12.4% |
| Revenue growth rate | 40.8% |
| Return on equity | 8.7% |
| Net Margin | 5.0% |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Gen Ilac Ve Saglik Urunleri Sanayi Ve Ticaret Anonim Sirketi makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 11,212 | 559 | 1,101 | 0 |
| 30 Jun 24 | 11,166 | 774 | 1,073 | 0 |
| 31 Mar 24 | 9,747 | 787 | 1,051 | 0 |
| 31 Dec 23 | 8,152 | 455 | 998 | 0 |
| 30 Sep 23 | 14,160 | -22 | 1,620 | 0 |
| 30 Jun 23 | 11,752 | -104 | 1,368 | 0 |
| 31 Mar 23 | 11,172 | 314 | 1,127 | 0 |
| 31 Dec 22 | 10,639 | 640 | 893 | 0 |
| 30 Sep 22 | 4,779 | 775 | 338 | 0 |
| 30 Jun 22 | 3,908 | 594 | 266 | 0 |
| 31 Mar 22 | 2,927 | 396 | 210 | 0 |
| 31 Dec 21 | 2,501 | 311 | 169 | 0 |
| 30 Sep 21 | 2,796 | 294 | 148 | 0 |
| 30 Jun 21 | 2,983 | 273 | 135 | 0 |
| 31 Mar 21 | 2,523 | 267 | 118 | 0 |
| 31 Dec 20 | 2,150 | 208 | 108 | 0 |
| 31 Dec 19 | 1,795 | 142 | 106 | 0 |
| 31 Dec 18 | 1,180 | 5 | 86 | 2 |
Quality Earnings: GENIL has a large one-off loss of TRY102.9M impacting its last 12 months of financial results to 30th September, 2024.
Growing Profit Margin: GENIL became profitable in the past.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: GENIL's earnings have grown significantly by 20% per year over the past 5 years.
Accelerating Growth: GENIL has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.
Earnings vs Industry: GENIL has become profitable in the last year, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (7.3%).
Return on Equity
High ROE: GENIL's Return on Equity (8.7%) is considered low.